AstraZeneca surpassed profitability expectations as it disclosed its third-quarter earnings, even as it confronts a significant legal challenge alleging that the effectiveness of its vaccines was greatly exaggerated.
US investment bank states that hVIVO is reinforced by powerful industry momentum.
Stifel’s Insight on hVIVO PLC
hVIVO PLC (AIM:HVO) Positive results from flu human challenge study
Positive results from influenza human challenge study conducted by hVIVO Pneumagen to advance antiviral candidate into further clinical studies
AstraZeneca (LON:AZN) reaches a monthly peak due to positive outcomes from a breast cancer medication trial.
Shares of AstraZeneca PLC (LSE: AZN) have witnessed a 2% increase, surpassing 11,100p for the first time in a month, following the company’s announcement of promising results from an ongoing
Scancell Holdings (AIM:SCLP OTC:SCNLF) jump 23% following trial data; analysts praise the outcomes
Scancell Holdings PLC (AIM: SCLP, OTC: SCNLF) shares soared by 23% in early market hours after it reported that the initial phase of its phase II SCOPE trial for advanced
hVIVO PLC (AIM:HVO) Interim results
Strong first-half performance and record forward visibility Upgrade of Full Year Revenue and EBITDA Guidance
AstraZeneca (LON:AZN) and Alexion collaborate with the FDA to broaden the US label for Ultomiris.
AstraZeneca PLC (LON: AZN) announced that the US Food and Drug Administration (FDA) has requested a risk assessment and mitigation strategy in response to a proposal to broaden the application
hVIVO PLC (AIM:HVO) Plans for a new larger state-of-the-art facility
Plans for a new larger state-of-the-art facility to meet growing demand
hVIVO PLC (AIM:HVO) Notice of Results
hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it will release its interim results for
AstraZeneca subsidiary finalizes a US$1bn deal with Pfizer for rare diseases.
AstraZeneca has reported a stronger-than-anticipated performance in the second quarter, with robust sales from its leading cancer drugs offsetting the decline in Covid vaccine sales.
hVIVO PLC (AIM & Euronext: HVO) Trading update
Strong first-half performance and record order book On track to deliver full-year guidance and long-term sustainable growth